Sentence: Patients with wild-type KRAS exon 2 mCRC previously treated with fluorouracil- , oxaliplatin- and irinotecan-based chemotherapies were randomised ( 1:1 ) to either panitumumab plus irinotecan ( panitumumab arm ) or cetuximab plus irinotecan ( cetuximab arm ) .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['panitumumab', 'irinotecan'], 'is_context_needed': True}, {'class': 'POS', 'spans': [6, 7], 'is_context_needed': True}]